Business Wire

Sotera Health’s Nelson Labs Announces Acquisition of New Jersey-Based Gibraltar Laboratories

Jaa

Sotera Health, the world’s leading, fully integrated protector of global health, announced today that it has acquired New Jersey-based Gibraltar Laboratories. This acquisition expands the U.S.-based analytical testing capabilities of Sotera Health’s Nelson Labs business. Gibraltar Laboratories is a leading outsourced provider of microbiology and analytical chemistry testing for pharmaceutical and medical device manufacturers. Terms of the deal were not disclosed.

Headquartered in Fairfield, New Jersey, Gibraltar Laboratories has an outstanding reputation for customer service, technical expertise and quality performance. Gibraltar is known for USP compendial microbiology, sterility assurance and analytical chemistry testing. The company, owned and operated by the Prince family since 1970, runs two laboratories in the New Jersey tri-state area.

“Gibraltar Laboratories is a well-respected laboratory known for its strong customer relationships with U.S.-based pharmaceutical manufacturers,” said Michael B. Petras Jr., CEO of Sotera Health. “In addition to its testing expertise, Gibraltar’s facilities are located in the Northeast pharmaceutical corridor, home to many of the top pharmaceutical manufacturers in the United States. This acquisition will expand our presence in this important region and further strengthen our testing capabilities for the pharmaceutical industry. We welcome Gibraltar’s strong management and expert staff as they join our mission of Safeguarding Global HealthTM.”

“Through the commitment of three generations of the Prince family, as well as our experienced staff of microbiology and chemistry professionals, we have earned a reputation as a reliable, responsive and highly professional partner for our customers, and we know we have found the same in Sotera Health,” said Dr. Daniel L. Prince, President of Gibraltar Laboratories. “My goal is for Gibraltar to continue to build on its long-standing reputation of excellence and continue to expand its offerings. We accomplish this by becoming part of Sotera Health, a global company whose breadth of services and expansive reach provide extraordinary value to the industries we are proud to serve.”

“Gibraltar’s offerings and the strategic location of its facilities will be a great benefit to our mutual customers, who value working with a trusted partner that can consistently deliver quality, service and expertise,” said Jeff Nelson, President of Nelson Labs. “The Gibraltar team is known for these values and also has an excellent reputation for designing specialized studies that help manufacturers prove the safety, efficacy and regulatory compliance of their products. I am also personally excited to be working directly with Dr. Daniel Prince, who I consider a leading thinker in our field.”

Gibraltar will complement Sotera Health’s Nelson Labs business. Gibraltar’s expertise in pharmaceutical products and analytical testing capabilities will enhance Nelson Labs’ existing strengths in medical device microbiology and expert advisory services. Gibraltar’s facilities are FDA registered and ISO 17025 accredited and have the distinction of being accredited for both the microbiological and chemical fields. The acquisition of Gibraltar Laboratories does not include Prince Sterilization Services, LLC. However, both companies are excited that Gibraltar will continue to maintain a partnership with Prince Sterilization Services to provide the testing needed to certify their products.

About Sotera Health: Sotera Health LLC, along with its business entities, is the world’s leading, fully integrated protector of global health. With over 500 years of combined scientific expertise, the company ensures the safety of healthcare by providing mission-critical services to the medical device, pharmaceutical, tissue and food industries. Sotera Health operates 63 facilities in 13 countries. The company has over 2,600 employees globally and touches the lives of more than 180 million people around the world each year. Sotera Health serves more than 5,000 customers worldwide, including 75 of the top 100 medical device manufacturers.

Sotera Health goes to market through its three best-in-class companies – Nelson Labs™, Nordion® and Sterigenics® – with the mission of ensuring the safety of health care each and every day. Nelson Labs offers microbiological and analytical testing and expert advisory services to assist customers in developing and maintaining sterilization solutions in medical devices, tissue/implantable products, and the pharmaceutical and biologics fields. Nordion is the world’s largest provider of Cobalt-60 used in the gamma sterilization process, and Sterigenics provides comprehensive contract sterilization and ionization solutions for the medical device, pharmaceutical, food safety and high-performance materials industries.

Sotera Health LLC is owned by private equity firms Warburg Pincus and GTCR. Learn more about Sotera Health at soterahealth.com, about Nelson Labs at nelsonlabs.com, about Nordion at nordion.com and about Sterigenics at sterigenics.com.

About Nelson Laboratories: Nelson Laboratories, LLC is the industry-leading provider of global lab testing and expert advisory services. Nelson Labs performs over 400 rigorous microbiological and analytical laboratory tests, including a best-in-class extractables and leachables testing platform, for the medical device, pharmaceutical and tissue industries. The company is regarded as a best-in-class partner with a strong track record of collaborating with customers to solve complex issues. With 11 global laboratory locations in 8 countries, Nelson Labs is committed to Safeguarding Global HealthTM with every test they complete.

About Gibraltar Laboratories: With an outstanding reputation for customer service, quality research, quality control and testing in stem cells, bacteriology, mycology, virology, chemistry, cleaning validations and in vitro toxicology, Gibraltar Laboratories has set the Gold Standard for contract laboratories. Gibraltar Laboratories proudly serves the pharmaceutical, medical device, orthopedic, tissue bank, biopharmaceutical, chemical, and cosmetic industries. The company operates two laboratories and is based in Fairfield, New Jersey. To learn more, visit www.gibraltarlabsinc.com.

Contact information

Dix & Eaton for SOTERA HEALTH:
Angela Martin, 216-241-2148
amartin@dix-eaton.com
or
GIBRALTAR LABORATORIES:
Danina Rinaldi, 973-227-6882 ext. 529
Technical Services Manager
drinaldi@gibraltarlabsinc.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

SCG Chemicals Company chooses gPROMS modelling for digital design and operations22.3.2019 18:55:00 EETTiedote

Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced that it has signed a long-term agreement with SCG, one of the largest integrated petrochemical companies in South East Asia, to standardise on PSE’s gPROMS® modelling technology for digital design and operations. SCG applies advanced process models within digital design initiatives to explore the process decision space rapidly and effectively, in order to reduce uncertainty and make better, faster and safer design and operating decisions. This help them to accelerate innovation and optimise the design and operation of their process plants. Dr Suracha Udomsak, SCG’s Emerging Business Director and R&D Director, says, “at SCG Chemicals, advanced process modelling (APM) is a key element in our Digital Manufacturing platform. APM accelerates innovation by making the development workflow ‘faster, cheaper & safer’, which are key considerations for us. It is a core technology building block that enables u

Logicor Announces Results for Year Ended 31 December 201822.3.2019 17:29:00 EETTiedote

Logicor announces strong financial performance for the year ended 31 December Net Operating Income (NOI): €639 million, which represents year on year growth of 2.5%, reflecting our strategic focus on increasing occupancy and capturing market rental growth. Over 60% of NOI is generated in the key markets of the UK (26%), Northern Europe1 (21%) and France (15%). Gross Asset Value: €12.5 billion, a 3.3% increase in valuation, which reflects the strong performance of our portfolio, in particular in Northern Europe. EPRA Occupancy: 94.4%, with physical occupancy up 70 bps over the year, underpinned by strong growth in each of our three largest regions of the UK (+120 bps), Northern Europe (+110 bps) and France (+220 bps). LTV: 51%, down from 52% at year end 2017 following increases in property values. At year end, our debt to EBITDA ratio was 11.3x. Capital Structure In 2018 Logicor (rated BBB (Stable) by S&P) established a Euro Medium Term Note (‘EMTN’) programme and raised €1.8 billion of

Delticom AG/Mytyres.co.uk: Buying Great Value Tyres Online Doesn’t Mean Missing out on Professional Fitting22.3.2019 17:15:00 EETTiedote

Spring is just around the corner, and it’s time for drivers to start thinking about changing to summer tyres. However, a tyre check may show that your current summer tyres are getting old, worn out, or have visible damage, such as cracks or bumps. If this is the case, then it's time for a new set of tyres. The legal minimum tread depth is 1.6 mm, however experts recommend significantly more – summer tyres should be replaced even if the tread depth is 3 mm. Regardless of mileage, you should change your tyres at least every eight to ten years. This is because the rubber starts to harden, the tyres lose grip on the road, and driving performance is affected. Of course, a set of four new tyres is a significant investment – authorised workshops can often charge between 250 and 350 pounds. If you want to save money, consider the alternatives: the result is an increasing number of customers turning to online shops such as Mytyres.co.uk to buy new tyres. The market share of tyres sold online ha

Trueman Man Clinic Achieves 10000 Surgery Milestone with Its SWITCH Operation22.3.2019 16:00:00 EETTiedote

Trueman Man Clinic Network announced that the 10,000th surgery utilizing its SWITCH Premature Ejaculation Surgery (Nerve Conservation), has been successfully completed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190322005013/en/ Trueman Man Clinic Network has been successfully completed the 10,000th surgery utilizing its SWITCH Premature Ejaculation Surgery (Nerve Conservation). The SWITCH Premature Ejaculation Surgery (SWITCH operation) developed in 2010 by Dr. Yang, the chief director of the Trueman Man Clinic Network, can reduce the side effects of penile neurectomy and maintain the stable reduction of the glans sensation. The Trueman Man Clinic Network is the leading hospitals for male enhancement surgeries in Korea consists of 11 clinics, with 16 doctors working. As of 2019, more than 43,000 man clinic surgeries have been performed. (Photo: Business Wire) The Trueman Man Clinic Network is the leading hospitals for m

Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible22.3.2019 14:22:00 EETTiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for DARZALEX®▼ (daratumumab) in combination with lenalidomide and dexamethasone (Rd) for the treatment of patients newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). “Today’s submission brings us one step closer to our goal of improving treatment outcomes for people newly diagnosed with multiple myeloma,” said José Antonio Burón Vidal, VP Medical Affairs, Europe, Middle East and Africa (EMEA), Janssen-Cilag Limited. “We are incredibly grateful to the patients and investigators who participated in the MAIA clinical trial programme and look forward to working closely with the regulatory authorities to secure approval of this new combination.” The submission is supported by data from the Phase 3 MAIA (MMY3008) study, which were presented at the 60th Annual Meeting of the American

Bartek Ingredients Expands Leadership Team22.3.2019 01:35:00 EETTiedote

Bartek Ingredients Inc. recently completed a 4,000 ton/year capacity expansion for its malic and food-grade fumaric acid production facility, and today it announces the expansion of its leadership team, with the hiring of Jeff Billig as Vice President of Marketing & Business Development and Heinrich G. Schaefer as International Sales Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005785/en/ The global leader in malic and fumaric acid ingredients expands its leadership team. (Photo: Business Wire) Bartek’s investment in both its team and facilities reinforces its position as the leader in malic and fumaric acid globally and aligns with its mission to facilitate growth and increase global reach to better serve existing customers and markets while opening up new ones. Bartek’s addition of Billig and Schaefer lays the foundation for additional resource investment in the near future while rapidly increasing its sa

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme